Enveric Biosciences, Inc. (ENVB)
USD 0.33
(-10.81%)
USD 0.33
(-10.81%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.09 Million | -17.14 Million | -11.45 Million | -3.88 Million | -2.45 Million | -2.56 Million |
| Net Income | -17.31 Million | -18.47 Million | -48.97 Million | -6.86 Million | -6.02 Million | -16.89 Million |
| Depreciation & Amortization | 408.03 Thousand | 435.2 Thousand | 681.61 Thousand | 120.87 Thousand | 2.26 Million | 2.9 Million |
| Deferred income taxes | 103.84 Thousand | -1.5 Million | -7.45 Million | - | 388.65 Thousand | 6.34 Million |
| Stock-based compensation | 2.15 Million | 2.62 Million | 12.59 Million | 1.97 Million | 586.49 Thousand | 1.25 Million |
| Change in working capital | -174.75 Thousand | -217.66 Thousand | 1.18 Million | -369.49 Thousand | 1.74 Million | -1.02 Million |
| Other non-cash items | 729.07 Thousand | -9300.00 | 30.51 Million | 1.24 Million | -1.4 Million | 4.85 Million |
| Investing Cash Flow | 11.66 Thousand | -584.16 Thousand | 2.19 Million | -44.14 Thousand | -284.33 Thousand | -3.63 Million |
| Investments in PPE | -5180.00 | -584.16 Thousand | -864.71 Thousand | -44.14 Thousand | -84.33 Thousand | - |
| Acquisitions | 16.84 Thousand | 958.03 Thousand | 3.05 Million | - | -200 Thousand | -3.64 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 16.85 | -958.03 Thousand | -675.00 | -44.14 | - | 6421.00 |
| Financing Cash Flow | -1.34 Million | 18.18 Million | 24.89 Million | 5531.27 | 560.00 | 2.69 Million |
| Debt repayment | - | - | - | -1.67 Million | -538 Thousand | -1.97 Million |
| Dividends payments | - | - | - | - | - | -2089.15 Billion |
| Common Stock Repurchased | -1.05 Million | - | - | - | - | - |
| Common Stock Issuance | - | 17.22 Million | 21.61 Million | 3.86 Million | 2.12 Million | 6.32 Million |
| Other Financing Activities | -291.08 Thousand | 958.03 Thousand | 3.28 Million | 5531.27 | 560.00 | -1.65 Million |
| Accounts receivables | - | - | - | - | 1.48 Million | 967.03 Thousand |
| Accounts payables | -103.84 Thousand | 263.68 Thousand | 383.19 Thousand | 267 Thousand | 222.67 Thousand | -2.1 Million |
| Inventory | - | - | - | - | -222.67 Thousand | - |
| Other working capital | -70.9 Thousand | -481.34 Thousand | 801.86 Thousand | -636.49 Thousand | 257.67 Thousand | -1.99 Million |
| Cash at beginning of period | 17.72 Million | 17.35 Million | 1.57 Million | 43.71 Thousand | 1.37 Million | 4.88 Million |
| Cash at end of period | 2.28 Million | 17.72 Million | 17.35 Million | 1.57 Million | 431.4 Thousand | 1.37 Million |
| Capital Expenditure | -5180.00 | -584.16 Thousand | -864.71 Thousand | -44.14 Thousand | -84.33 Thousand | - |
| Effect of forex changes on cash | -10.02 Thousand | -81.36 Thousand | 144.94 Thousand | -63.59 Thousand | -1.00 | -3.74 |
| Net cash flow / Change in cash | -15.43 Million | 367.88 Thousand | 15.77 Million | 1.53 Million | -939.93 Thousand | -3.51 Million |
| Free Cash Flow | -14.09 Million | -17.73 Million | -12.32 Million | -3.93 Million | -2.53 Million | -2.56 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.87 Million | -2.45 Million | -17.31 Million | -3.43 Million | -2.82 Million | -6.35 Million |
| Depreciation & Amortization | 84.77 Thousand | 85.4 Thousand | 408.03 Thousand | 84.68 Thousand | 95.83 Thousand | 114.37 Thousand |
| Deferred income taxes | - | - | 103.84 Thousand | -1.06 Million | -3.35 Million | - |
| Stock-based compensation | 369.61 Thousand | 351.48 Thousand | 2.15 Million | 364.72 Thousand | 372.85 Thousand | 879.73 Thousand |
| Change in working capital | -1.44 Million | -556.89 Thousand | -174.75 Thousand | 205.83 Thousand | 243.62 Thousand | 298.27 Thousand |
| Other non-cash items | 2.18 Million | 298.47 Thousand | 729.07 Thousand | 2.09 Million | 2.72 Million | 597.75 Thousand |
| Investing Cash Flow | - | - | 11.66 Thousand | -38.00 | 20.00 | 16.85 Thousand |
| Investments in PPE | 3.00 | - | -5180.00 | 15.00 | -8.00 | -18.00 |
| Acquisitions | - | - | 16.84 Thousand | -53.00 | 28.00 | 16.87 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 16.85 | -0.05 | 0.03 | 16.87 |
| Financing Cash Flow | 34.43 Thousand | 6.65 Million | -1.34 Million | -186.08 Thousand | -105 Thousand | -1.05 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -1.05 Million | 1.05 Million | - | -1.05 Million |
| Common Stock Issuance | 51.68 Thousand | 6.8 Million | - | - | - | - |
| Other Financing Activities | -17.25 Thousand | -144.05 Thousand | -291.08 Thousand | -186.08 Thousand | -105 Thousand | -1052.06 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -1.66 Million | 202.39 Thousand | -103.84 Thousand | -533.53 Thousand | -112.7 Thousand | -111.31 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 215.46 Thousand | -759.28 Thousand | -70.9 Thousand | 739.37 Thousand | 356.33 Thousand | 409.58 Thousand |
| Cash at beginning of period | 6.35 Million | 2.28 Million | 17.72 Million | 4.26 Million | 7.08 Million | 12.56 Million |
| Cash at end of period | 3.5 Million | 6.35 Million | 2.28 Million | 2.28 Million | 4.26 Million | 7.08 Million |
| Capital Expenditure | 3.00 | - | -5180.00 | 15.00 | -8.00 | -18.00 |
| Effect of forex changes on cash | 1258.00 | 8137.00 | -10.02 Thousand | -41.42 Thousand | 30.57 Thousand | 20.71 Thousand |
| Net cash flow / Change in cash | -2.85 Million | 4.06 Million | -15.43 Million | -1.97 Million | -2.81 Million | -5.48 Million |
| Free Cash Flow | -2.88 Million | -2.59 Million | -14.09 Million | -1.75 Million | -2.74 Million | -4.46 Million |
SLROF
AFFORDABLE
RAINBOWF
CPAU
DEEZR
SVRT